Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
McKesson
Moodys
AstraZeneca
Dow

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,476,225

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 8,476,225
Title:Antiviral compounds
Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s): Casarez; Anthony (Princeton, NJ), Ji; Mingzhe (Union City, CA), Kim; Choung U. (San Carlos, CA), Sheng; Xiaoning C. (Foster City, CA), Wu; Qiaoyin (Foster City, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/958,086
Patent Claims:1. A compound of formula 1: ##STR00213## or a pharmaceutically acceptable salt thereof; wherein: R.sub.1 is R.sub.2--, R.sub.2--C(O)--, R.sub.2--O--C(O)-- or R.sub.2--N(H)--C(O)-- R.sub.2 is optionally substituted C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally substituted C.sub.7-C.sub.14 cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycle or optionally substituted heterocyclylalkyl; R.sub.3 is optionally substituted C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally substituted C.sub.7-C.sub.14 cycloalkylalkyl, optionally substituted heterocyclylalkyl, or optionally substituted heterocycle, or R.sub.3 and R.sub.8, along with the atoms that connect them, form a 12 to 18 membered saturated, partially unsaturated or unsaturated heterocycle wherein the 12 to 18 membered saturated, partially unsaturated or unsaturated heterocycle is optionally substituted with C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6-haloalkyl, halo, oxo or cyano and wherein 0, 1, 2, or 3 carbon atoms of R.sub.3 are optionally replaced by O, N, or S; R.sub.4 is R.sub.6--, R.sub.6--R.sub.5--, R.sub.6--W--, R.sub.6--W--C(O)--, R.sub.6--C(O)--, R.sub.6--C(O)--W--, R.sub.6--W--O--C(O)--, R.sub.6--S(O).sub.m--, R.sub.6--W--S(O).sub.m--, R.sub.6--N(H)--C(O)--, R.sub.6--N(H)--S(O).sub.m--, R.sub.6--R.sub.5--S(O).sub.m--, or R.sub.6--N(H)--R.sub.5--; R.sub.5 is optionally substituted arylene or optionally substituted heteroarylene; R.sub.6 is optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally substituted aryl or optionally substituted heterocycle; m is 0, 1 or 2: W is C.sub.1-C.sub.4 alkylene, C.sub.2-C.sub.4 alkenylene, or C.sub.2-C.sub.4alkynylene wherein the C.sub.1-C.sub.4 alkylene, C.sub.2-C.sub.4 alkenylene, or C.sub.2-C.sub.4 alkynylene is optionally substituted with C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-haloalkyl, cyano or halo; R.sub.7 is: ##STR00214## R.sub.8 is C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl or C.sub.2-C.sub.4-alkynyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl or C.sub.2-C.sub.4-alkynyl is optionally substituted with halo or cyano; R.sub.9 is R.sub.10, R.sub.10--NH-- or R.sub.10--O-- R.sub.10 is C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halo; R.sub.11 is C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, C.sub.1-C.sub.4-alkylthio, cyano or halo; each R.sub.12 is independently H, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl wherein the C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halo; R.sub.13 is H, OH, OR.sub.14, C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.4-C.sub.12 cycloalkylalkyl, aryl, arylalkyl, heterocycle or heterocyclylalkyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.4-C.sub.12 cycloalkylalkyl, aryl, arylalkyl, heterocycle or heterocyclylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl cyano or halo; R.sub.14 is R.sub.15--, R.sub.15--C(O)--, R.sub.15--O--C(O)--, or R.sub.15O--C(O)--X-- R.sub.15 is C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, C.sub.7-C.sub.12 cycloalkylalkyl, aryl, arylalkyl, heterocycle, or heterocyclylalkyl wherein the C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.7 cycloalkyl, or C.sub.7-C.sub.12 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halo; X is C.sub.1-C.sub.5 alkylene or C.sub.3-C.sub.6 spiroalkylene; R.sub.16 is H, R.sub.17--C(O)--, R.sub.17--O--C(O)-- or R.sub.17O--C(O)--X--; each R.sub.17 is independently H, C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halo, or two R.sub.17, along with the carbon to which they are attached, form a 3-6 membered spirocyclic carbocycle or heterocycle wherein any carbon of said carbocycle or heterocycle is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halo and any nitrogen of said heterocycle is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, C.sub.3-C.sub.5 cycloalkyl or C.sub.1-C.sub.3 acyl, or, taken together, two instances of R.sub.17 together with the carbon atom to which they are attached form a carbonyl group.

2. A compound according to claim 1 wherein R.sub.7 is ##STR00215##

3. A compound according to claim 1 wherein R.sub.9 is R.sub.10.

4. A compound according to claim 3 wherein R.sub.1 is R.sub.2--O--C(O)--.

5. A compound according to claim 4 wherein R.sub.2 is optionally substituted C.sub.1-C.sub.8 alkyl, optionally substituted C.sub.3-C.sub.10 cycloalkyl or optionally substituted C.sub.7-C.sub.14 cycloalkylalkyl.

6. A compound according to claim 1 wherein each R.sub.17 is independently H or substituted alkyl.

7. A compound of claim 1 wherein R.sub.4 is ##STR00216## ##STR00217## ##STR00218## ##STR00219##

8. A compound according to claim 2 wherein R.sub.1 is cyclopentyloxycarbonyl, t-butyloxycarbonyl, or 2,2,2-trifluoro-1,1-dimethylethyloxycarbonyl.

9. A compound according to claim 2 wherein R.sub.2 is cyclopentyl, t-butyl or 2,2,2-trifluoro-1,1-dimethylethyl.

10. A compound according to claim 2 wherein R.sub.3 is t-butyl.

11. A compound according to claim 2 wherein R.sub.3 and R.sub.8 together form ##STR00220##

12. A compound according to claim 2 wherein R.sub.4 is R.sub.6-alkylene-, R.sub.6-alkylene-C(O)--, R.sub.6--C(O)-alkylene-, R.sub.6--C(O)--, R.sub.6--S(O).sub.2--, R.sub.6-alkylene-S(O).sub.2--, R.sub.6--NH--C(O)--, R.sub.6--NH--S(O).sub.2--, R.sub.6--, R.sub.6--R.sub.5--, R.sub.6--R.sub.5--S(O).sub.2--, or R.sub.6--NH--R.sub.5--.

13. A compound according to claim 2 wherein R.sub.5 is ##STR00221##

14. A compound according to claim 2 wherein R.sub.6 is ##STR00222##

15. A compound according to claim 1 wherein R.sub.7 is ##STR00223##

16. A compound according to claim 1 wherein R.sub.7 is ##STR00224##

17. A compound according to claim 1 wherein R.sub.7 is ##STR00225##

18. A compound according to claim 1 wherein R.sub.7 is ##STR00226##

19. A compound according to claim 2 wherein R.sub.8 is ethyl or ethylene.

20. A compound according to claim 2 wherein R.sub.9 is R.sub.10.

21. A compound according to claim 2 wherein R.sub.10 is cyclopropyl or 1-methylcyclopropyl.

22. A compound according to claim 15 wherein R.sub.11 is cyclobutylmethyl or n-propyl.

23. A compound according to claim 15 wherein each R.sub.12 is independently H or cyclopropyl.

24. A compound according to claim 18 wherein R.sub.13 is alkyl, optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl.

25. A compound according to claim 24 wherein R.sub.16 is H, R.sub.17--C(O)--, R.sub.17--O--C(O)-- or R.sub.17--O--C(O)--X--.

26. A compound according to claim 25 wherein R.sub.17 is alkyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycle, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl.

27. A compound selected from the group consisting of ##STR00227## ##STR00228## ##STR00229## ##STR00230## ##STR00231## ##STR00232## ##STR00233## ##STR00234## ##STR00235## ##STR00236## ##STR00237## ##STR00238## ##STR00239## ##STR00240## ##STR00241## ##STR00242## ##STR00243## ##STR00244## ##STR00245##

28. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

29. The pharmaceutical composition of claim 28, further comprising at least one additional therapeutic agent.

30. The pharmaceutical composition of claim 29, wherein said additional therapeutic agent is selected from the group consisting of interferons, ribavirin analogs, NS5a inhibitors, NS4b inhibitors, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, and non-nucleoside inhibitors of HCV.

31. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of pegylated rIFN-alpha 2b (PEG-Intron), pegylated rIFN-alpha 2a (Pegasys), rIFN-alpha 2b (Intron A), rIFN-alpha 2a (Roferon-A), interferon alpha (MOR-22, OPC-18, Alfaferone, Alfanative, Multiferon, subalin), interferon alfacon-1 (Infergen), interferon alpha-n1 (Wellferon), interferon alpha-n3 (Alferon), interferon-beta (Avonex, DL-8234), interferon-omega (omega DUROS, Biomed 510), albinterferon alpha-2b (Albuferon), IFN alpha XL, BLX-883 (Locteron), DA-3021, glycosylated interferon alpha-2b (AVI-005), PEG-Infergen, PEGylated interferon lambda (PEGylated IL-29), and belerofon.

32. The pharmaceutical composition of claim 28, further comprising at least one additional therapeutic agent selected from the group consisting of ribavirin (Rebetol, Copegus), and taribavirin (Viramidine).

33. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of boceprevir (SCH-503034 , SCH-7), telaprevir (VX-950), VX-813, TMC-435 (TMC435350), ABT-450, BI-201335, BI-1230, MK-7009, SCH-900518, VBY-376, VX-500, GS-9256, GS-9451, BMS-790052, BMS-605339, PHX-1766, AS-101, YH-5258, YH5530, YH5531, and ITMN-191 (R-7227).

34. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of celgosivir (MX-3253), Miglitol, and UT-231B.

35. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of emericasan (IDN-6556), ME-3738, GS-9450 (LB-84451), silibilin, and MitoQ, 6) nucleoside or nucleotide inhibitors of HCV NS5B polymerase, R1626, R7128 (R4048), IDX184, IDX-102, PSI-7851, BCX-4678, valopicitabine (NM-283), and MK-0608.

36. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of filibuvir (PF-868554), ABT-333, ABT-072, BI-207127, VCH-759, VCH-916, JTK-652, MK-3281, GS-9190, VBY-708, VCH-222, A848837, ANA-598, GL60667, GL59728, A-63890, A-48773, A-48547, BC-2329, VCH-796 (nesbuvir), GSK625433, BILN-1941, XTL-2125, and GS-9190.

37. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of AZD-2836 (A-831), AZD-7295 (A-689), and BMS-790052.

38. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of imiquimod, 852A, GS-9524, ANA-773, ANA-975, AZD-8848 (DSP-3025), PF-04878691, and SM-360320, cyclophillin inhibitors, e.g., DEBIO-025, SCY-635, and NIM811 and HCV IRES inhibitors, e.g., MCI-067.

39. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of BAS-100, SPI-452, PF-4194477, TMC-41629, GS-9350, GS-9585, and roxythromycin.

40. The pharmaceutical composition of claim 29, further comprising at least one additional therapeutic agent selected from the group consisting of thymosin alpha 1 (Zadaxin), nitazoxanide (Alinea, NTZ), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), GS-9525, KRN-7000, civacir, GI-5005, XTL-6865, BIT225, PTX-111, ITX2865, TT-033i, ANA 971, NOV-205, tarvacin, EHC-18, VGX-410C, EMZ-702, AVI 4065, BMS-650032, BMS-791325, Bavituximab, MDX-1106 (ONO-4538), Oglufanide, FK-788, and VX-497 (merimepodib).

41. The pharmaceutical composition according to claim 29, further comprising a nucleoside analogue.

42. The pharmaceutical composition according to claim 41, further comprising an interferon or pegylated interferon.

43. The pharmaceutical composition according to claim 42, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine and wherein said interferon is .alpha.-interferon or pegylated interferon.

44. A method of treating HCV infection, said method comprising administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

45. A compound of formula 1: ##STR00246## or a pharmaceutically acceptable salt thereof; wherein: R.sub.1 is R.sub.2--O--C(O)--; R.sub.2 is C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.10 cycloalkyl or C.sub.7-C.sub.14cycloalkylalkyl, wherein each C.sub.1-C.sub.8 alkyl, C.sub.3-C.sub.10 cycloalkyl and C.sub.7-C.sub.14 cycloalkylalkyl is optionally substituted with one or more F, Cl, Br, or I; R.sub.3 is t-butyl; or R.sub.3 and R.sub.8 together form: ##STR00247## R.sub.4 is R.sub.6--, R.sub.6--R.sub.5--, R.sub.6--W--, R.sub.6--W--C(O)--, R.sub.6--C(O)--, R.sub.6--C(O)--W--, R.sub.6--W--O--C(O)--, R.sub.6--S(O).sub.m--, R.sub.6--W--S(O).sub.m--, R.sub.6--N(H)--C(O)--, R.sub.6--N(H)--S(O).sub.m--, R.sub.6--R.sub.5--S(O).sub.m--, or R.sub.6--N(H)--R.sub.5--; R.sub.5 is optionally substituted arylene or optionally substituted heteroarylene, wherein said arylene or heteroarylene is optionally substituted with one or more alkyl, alkoxy, haloalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, aryl, heterocycle, halogen, cyano, azido, amino, nitro, sulfonamide, alkylsulfonyl, or carboxamido; R.sub.6 is C.sub.3-C.sub.10 cycloalkyl, aryl or heterocycle, wherein said C.sub.3-C.sub.10 cycloalkyl, aryl or heterocycle is optionally substituted with one or more alkyl, alkoxy, haloalkyl, cycloalkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, aryl, heterocycle, halogen, cyano, azido, amino, nitro, sulfonamide, alkylsulfonyl, and carboxamido; m is 0, 1 or 2; W is C.sub.1-C.sub.4 alkylene, C.sub.2-C.sub.4 alkenylene, or C.sub.2-C.sub.4 alkynylene wherein the C.sub.1-C.sub.4 alkylene, C.sub.2-C.sub.4 alkenylene, or C.sub.2-C.sub.4 alkynylene is optionally substituted with C.sub.1-C.sub.3-alkyl, C.sub.1-C.sub.3-haloalkyl, cyano or halogen; R.sub.7 is: ##STR00248## ##STR00249## R.sub.8 is C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl or C.sub.2-C.sub.4-alkynyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.2-C.sub.4 alkenyl or C.sub.2-C.sub.4-alkynyl is optionally substituted with halogen or cyano; R.sub.9 is R.sub.10; R.sub.10 is C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl wherein the C.sub.1-C.sub.4 alkyl, C.sub.3-C.sub.7 cycloalkyl or C.sub.4-C.sub.9 cycloalkylalkyl is optionally substituted with C.sub.1-C.sub.2-alkyl, C.sub.1-C.sub.2-haloalkyl, cyano or halogen; R.sub.11 is cyclobutylmethyl or n-propyl; each R.sub.12 is independently H or cyclopropyl; and each R.sub.17 is independently H or C.sub.1-C.sub.4 alkyl.

Details for Patent 8,476,225

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16   Start Trial Gilead Sciences, Inc. (Foster City, CA) 2029-12-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Merck
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.